Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My Cart

Main menu

  • Home
  • Articles
    • Archive
  • About the Journal
    • About CVI
    • For Librarians
    • For Advertisers
    • FAQ
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My Cart

Search

  • Advanced search
Clinical and Vaccine Immunology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Archive
  • About the Journal
    • About CVI
    • For Librarians
    • For Advertisers
    • FAQ
NOTE

Anticytomegalovirus (Anti-CMV) Immunoglobulin G Avidity in Identification of Pregnant Women at Risk of Transmitting Congenital CMV Infection

Tiziana Lazzarotto, Patrizia Spezzacatena, Stefania Varani, Liliana Gabrielli, Paola Pradelli, Brunella Guerra, Maria Paola Landini
Tiziana Lazzarotto
Department of Clinical and Experimental Medicine, Section of Microbiology and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrizia Spezzacatena
Department of Clinical and Experimental Medicine, Section of Microbiology and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefania Varani
Department of Clinical and Experimental Medicine, Section of Microbiology and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liliana Gabrielli
Department of Clinical and Experimental Medicine, Section of Microbiology and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paola Pradelli
Department of Clinical and Experimental Medicine, Section of Microbiology and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brunella Guerra
Second Department of Obstetrics and Gynecology, Medical School, University of Bologna, Bologna, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Paola Landini
Department of Clinical and Experimental Medicine, Section of Microbiology and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/CDLI.6.1.127-129.1999
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

In this work, we show that the determination of the anticytomegalovirus antibody avidity carried out before week 18 of gestation is a helpful tool to identify women for enrollment in prenatal diagnosis. This procedure can identify all pregnant women who will give birth to an infected newborn.

Congenital cytomegalovirus (CMV) infection is the leading cause of congenital viral infection in developed countries, occurring in approximately 1% of all live births (1, 3, 4, 9, 18). Transmission of CMV to the fetus follows approximately 40% of primary maternal infections, whereas approximately 0.5% of women who are seropositive before pregnancy deliver infected infants (17). In addition, symptomatic infections and debilitating sequelae are rare in congenitally infected children born to women with preexisting immunity to CMV (5).

Diagnosis of primary CMV infection in immunocompetent adults is accomplished by serological methods (3). CMV-specific immunoglobulin M (IgM) is a sensitive indicator of an ongoing or recent infection. However, it is not a specific indicator of primary infection, as it is often produced during nonprimary infections (2, 10, 15). Another serological procedure useful in identifying primary infections is the determination of IgG avidity (6, 8, 11, 13).

In this work, we determined the avidity index (AI) of anti-CMV antibody in 76 pregnant women at risk of transmitting CMV to their offspring as well as in 20 pregnant women at no risk of transmitting CMV. All the women went through prenatal diagnoses, and pregnancy outcomes were monitored.

Between January 1994 and May 1998, 76 pregnant women were enrolled in the prenatal diagnosis program for CMV infection either because of a seroconversion for CMV during the first trimester of pregnancy (n = 15) or because of the presence of CMV-specific IgM (n = 61).

Twenty pregnant women at no risk of fetal CMV transmission (as determined by a negative IgM test) but who had amniotic fluid (AF) and fetal blood taken for fetal karyotype assessment constituted a control group. Twenty milliliters of AF was collected by amniocentesis at 21 to 23 weeks’ gestation with informed consent from all women. CMV DNA was individually extracted from 3 to 6 aliquots of AF (100 μl each), and PCR was carried out as described in detail previously (12). AF was considered positive if at least one of the aliquots was positive.

Congenital CMV infection in a newborn was determined by CMV isolation (7) from urine or saliva during the first week of life.

The determination of IgG avidity was carried out using a commercial kit (Cytomegalovirus IgG avidity EIA WELL; RADIM, Rome, Italy).

As shown in Table 1, we obtained blood samples from 76 pregnant women during the early phase of pregnancy (6 to 18 weeks’ gestation; mean, 13.6 weeks). Anti-CMV antibody avidity was determined, and in only six cases it was not possible because of an IgG level that was too low. Of these women, one with congenital hypogammaglobulinemia who was found to be PCR positive in AF testing decided to interrupt her pregnancy. No sign of CMV infection was found in the fetus. The other five women continued their pregnancies, and no congenitally infected newborn was documented. In the remaining 70 samples, the AI was determined, and the women were classified into one of the following three groups on the basis of the result obtained: low AI (38 cases), moderate AI (6 cases), and high AI (26 cases). Of the 38 women who showed a low avidity, 17 had the viral genome in the AF (45%) as detected by PCR. Thirteen women (seven who seroconverted and six who were IgM positive) continued their pregnancies, and the virus was isolated from six newborns (four asymptomatic and two symptomatic). Four women (one who seroconverted and three who were IgM positive) decided to interrupt their pregnancies, and all four fetuses showed the presence of CMV in multiple organs (data not shown). A detailed analysis of the results obtained on prenatal diagnoses has been recently published (12).

View this table:
  • View inline
  • View popup
Table 1.

Avidity index of anti-CMV IgG at two different gestation times in relation to prenatal diagnosis carried out by PCR in amniotic fluid and pregnancy outcomes in pregnant women at risk of transmitting a CMV infection and in a control population

Among the six women with moderate avidity, two had the viral genome in the AF (33%). All of them decided to continue their pregnancies, and no congenital infection was documented in their newborns. Finally, of 26 women with high AI, 3 had the viral genome in the AF (11%). All of them continued their pregnancies and no congenital infection was documented in their newborns.

Later during pregnancy (at the time of amniocentesis, i.e., after 21 to 23 weeks’ gestation), another blood sample was obtained from the same 76 pregnant women, and the AI was redetermined. As shown in the table, the six samples with IgG levels too low to allow the determination of AI at the first testing were again found to have low anti-CMV IgG levels at the time of amniocentesis, and the AI could not be determined. All six women had CMV-specific IgM, and one was excreting the virus in urine. One of them suffered from congenital hypogammaglobulinemia, and in four cases the presence of CMV-specific IgM was not confirmed by blot, suggesting a false IgM positivity at the first testing. No explanation for the observed delay in IgG development for the other IgM-positive woman was found.

Of the 38 women who had anti-CMV antibody with low avidity at the first testing, 32 (84%) still had a low AI at the time of amniocentesis. The other six had reached either a moderate or a high avidity. Among the 32 women who still had a low AI at the time of amniocentesis, 6 (19%) had a congenitally infected fetus or newborn. Among the 6 women with a moderate avidity and the 32 with a high avidity at the time of amniocentesis, one and three congenitally infected fetuses or newborns, respectively, were documented.

We also determined the anti-CMV IgG avidity of 20 pregnant women who had amniocentesis carried out due to genetic problems. The AI was higher than 60% for all of them (data not shown). PCR carried out on their AFs gave negative results, and no congenitally infected newborns were found. From the data presented, we calculated the sensitivity and specificity and the positive and negative predictive values of avidity determination with regard to the outcome of pregnancy (Table 1).

The main finding of this article is that if the determination of the anti-CMV antibody avidity is carried out early enough (before 18 weeks), it can identify all pregnant women who will transmit congenital CMV infection to their offspring. Furthermore, if the determination of AI is carried out later on during pregnancy, 60% of the women who will transmit the infection still have antibody with low avidity, while the others have developed a moderate or high avidity.

Interestingly, PCR detected viral DNA in the AF of 17 of 76 women, and in only 10 of the samples did we document a congenital infection in fetuses or newborns. This is probably due to the high sensitivity of the procedure, which detects a viral load so low as to be cleared by the fetal defenses, and is consistent with other published data (14, 16). Quantitative PCR is in progress to verify this hypothesis.

In conclusion, the early determination of anti-CMV antibody avidity is a helpful tool to identify a subgroup of IgM-positive women to enroll in prenatal diagnosis.

ACKNOWLEDGMENTS

This work was partially supported by Istituto Superiore di Sanità, Progetto, Sicurezza del Sangue e dei suoi Prodotti (1996) and the AIDS projects (1997 and 1998) and by the Italian Ministry of Education (40 and 60%).

FOOTNOTES

    • Received 6 July 1998.
    • Returned for modification 17 August 1998.
    • Accepted 30 September 1998.
  • Copyright © 1999 American Society for Microbiology

REFERENCES

  1. 1.↵
    1. Alford C. A.,
    2. Stagno S.,
    3. Pass R. F.,
    4. Britt W. J.
    Congenital and perinatal cytomegalovirus infections. Rev. Infect. Dis. 12 1990 S743 S745
    OpenUrl
  2. 2.↵
    1. Basson J.,
    2. Tardy J. C.,
    3. Aymard M.
    Pattern of anti-cytomegalovirus IgM antibodies determined by immunoblotting. A study of kidney graft recipients developing a primary or recurrent CMV infection. Arch. Virol. 108 1989 259 270
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Britt W. J.,
    2. Alford C. A.
    Cytomegalovirus Fields Virology 3rd ed. Fields B. N., Knipe D. M., Howley P. M., et al. 1996 2493 2523 Lippincott-Raven Publishers Philadelphia, Pa
  4. 4.↵
    1. Donner C.,
    2. Liesnard C.,
    3. Brancart F.,
    4. Rodesch F.
    Accuracy of amniotic fluid testing before 21 weeks’ gestation in prenatal diagnosis of congenital cytomegalovirus infection. Prenatal. Diagn. 14 1994 1055 1059
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Fowler K. B.,
    2. Stagno S.,
    3. Pass R. F.,
    4. Britt W. J.,
    5. Boll T. J.,
    6. Alford C. A.
    The outcome of congenital cytomegalovirus in relation to maternal antibody status. N. Engl. J. Med. 326 1992 663 667
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Genevieve R. E.,
    2. Barjot P.,
    3. Campet M.,
    4. Vabret A.,
    5. Herlicoviez M.,
    6. Muller G.,
    7. Levy G.,
    8. Guillois B.,
    9. Freymuth F.
    Evaluation of virological procedures to detect fetal human cytomegalovirus infection: avidity of IgG antibodies, virus detection in amniotic fluid and maternal serum. J. Med. Virol. 50 1996 9 15
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Gleaves C. A.,
    2. Smith T. F.,
    3. Shuster E. A.,
    4. Pearson G. R.
    Rapid detection of cytomegalovirus in MRC-5 cells inoculated with urine specimens by using low-speed centrifugation and monoclonal antibody to an early antigen. J. Clin. Microbiol. 19 1984 917 919
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Grangeot-Keros L.,
    2. Mayaux M. J.,
    3. Lebon P.,
    4. Freymuth F.,
    5. Eugene G.,
    6. Stricker R.,
    7. Dussaix E.
    Value of cytomegalovirus (CMV) IgG avidity for the diagnosis of primary CMV infection in pregnant women. J. Infect. Dis. 175 1997 944 946
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Ho M.
    Epidemiology of cytomegalovirus infections. Rev. Infect. Dis. 12 1990 S701 S710
    OpenUrlCrossRef
  10. 10.↵
    1. Kraat Y. J.,
    2. Stals F. S.,
    3. Christiaans M. H.,
    4. Lazzarotto T.,
    5. Landini M. P.,
    6. Bruggeman C. A.
    IgM antibody detection of ppUL80a and ppUL32 by immunoblotting: an early parameter for recurrent cytomegalovirus infection in renal transplant recipients. J. Med. Virol. 48 1996 289 294
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Lazzarotto T.,
    2. Spezzacatena P.,
    3. Pradelli P.,
    4. Abate D. A.,
    5. Varani S.,
    6. Landini M. P.
    Avidity of immunoglobulin G directed against human cytomegalovirus during primary and secondary infections in immunocompetent and immunocompromised subjects. Clin. Diagn. Lab. Immunol. 4 1997 469 473
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Lazzarotto T.,
    2. Guerra B.,
    3. Spezzacatena P.,
    4. Varani S.,
    5. Gabrielli L.,
    6. Pradelli P.,
    7. Rumpianesi F.,
    8. Banzi C.,
    9. Bovicelli L.,
    10. Landini M. P.
    Prenatal diagnosis of congenital cytomegalovirus infection. J. Clin. Microbiol. 36 1998 3540 3544
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Lutz E.,
    2. Ward K. N.,
    3. Gray J. J.
    Maturation of antibody avidity after primary human cytomegalovirus infection is delayed in immunosuppressed solid organ transplant patients. J. Med. Virol. 44 1994 317 322
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. Lynch L.,
    2. Daffos F.,
    3. Emanuel D.,
    4. Giovangrandi Y.,
    5. Meisel R.,
    6. Forestier F.,
    7. Cathomas G.,
    8. Berkowitz R. L.
    Prenatal diagnosis of fetal cytomegalovirus infection. Am. J. Obstet. Gynecol. 165 1991 714 718
    OpenUrlPubMedWeb of Science
  15. 15.↵
    1. Nielsen C. M.,
    2. Hansen K.,
    3. Andersen H. M. K.,
    4. Gerstoft J.,
    5. Vestergaard B. F.
    An enzyme labelled nuclear antigen immunoassay for detection of cytomegalovirus IgM antibodies in human serum: specific and nonspecific reactions. J. Med. Virol. 22 1987 67 76
    OpenUrlPubMed
  16. 16.↵
    1. Revello M. G.,
    2. Baldanti F.,
    3. Furione M.,
    4. Sarasini A.,
    5. Percivalle E.,
    6. Zavattoni M.,
    7. Gerna G.
    Polymerase chain reaction for prenatal diagnosis of congenital human cytomegalovirus infection. J. Med. Virol. 47 1995 462 466
    OpenUrlPubMedWeb of Science
  17. 17.↵
    1. Stagno S.,
    2. Pass R. F.,
    3. Dworsky M. E.,
    4. Henderson R. E.,
    5. Moore E. G.,
    6. Walton P. D.,
    7. Alford C. A.
    Congenital cytomegalovirus infection: the relative importance of primary and recurrent maternal infection. N. Engl. J. Med. 306 1982 945 949
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. Whitley R. J.,
    2. Kimberlin D. W.
    Treatment of viral infections during pregnancy and the neonatal period. Clin. Perinatol. 24 1997 267 283
    OpenUrlPubMedWeb of Science
PreviousNext
Back to top
Download PDF
Citation Tools
Anticytomegalovirus (Anti-CMV) Immunoglobulin G Avidity in Identification of Pregnant Women at Risk of Transmitting Congenital CMV Infection
Tiziana Lazzarotto, Patrizia Spezzacatena, Stefania Varani, Liliana Gabrielli, Paola Pradelli, Brunella Guerra, Maria Paola Landini
Clinical and Diagnostic Laboratory Immunology Jan 1999, 6 (1) 127-129; DOI: 10.1128/CDLI.6.1.127-129.1999

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Email

Thank you for sharing this Clinical and Vaccine Immunology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Anticytomegalovirus (Anti-CMV) Immunoglobulin G Avidity in Identification of Pregnant Women at Risk of Transmitting Congenital CMV Infection
(Your Name) has forwarded a page to you from Clinical and Vaccine Immunology
(Your Name) thought you would be interested in this article in Clinical and Vaccine Immunology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Anticytomegalovirus (Anti-CMV) Immunoglobulin G Avidity in Identification of Pregnant Women at Risk of Transmitting Congenital CMV Infection
Tiziana Lazzarotto, Patrizia Spezzacatena, Stefania Varani, Liliana Gabrielli, Paola Pradelli, Brunella Guerra, Maria Paola Landini
Clinical and Diagnostic Laboratory Immunology Jan 1999, 6 (1) 127-129; DOI: 10.1128/CDLI.6.1.127-129.1999
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About CVI
  • For Librarians
  • For Advertisers
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • Submit a Manuscript to mSphere

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 1556-6811; Online ISSN: 1556-679X